A new Alzheimer’s drug exposes a ‘fundamentally flawed’ part of how the US pays for drugs


Good morning, and welcome back to Insider Healthcare. I’m Andrew Dunn, and today in healthcare news:

If you’re new to this newsletter, sign up here. And let me know what we should be paying attention to going forward: [email protected]. On to the news:

Alzheimer's brain scan
Maree Valenta, who has Alzheimer’s disease, undergoes a scan to detect early Alzheimer’s in 2004. Photo by Fairfax Media via Getty Images/Fairfax Media via Getty Images via Getty Images

Doctors stand to make thousands on a new Alzheimer’s drug even if they don’t believe it works. It reveals a ‘fundamentally flawed’ part of America’s healthcare system.

Read more on Aduhelm’s budget-breaking potential here >>

Pfizer BioNTech COVID-19 vaccine
Pfizer BioNTech COVID-19 vaccine Pete Bannan/MediaNews Group/Daily Local News via Getty Images

US will likely miss Biden’s July 4 COVID-19 goal of having 70% of adults vaccinated, White House says

Read more here >>

GlaxoSmithKline Emma Walmsley
GlaxoSmithKline CEO Emma Walmsley. Mandel Ngan/Getty Images

With activist investor Elliott breathing down GSK’s neck, here are 5 burning questions the pharma giant needs to answer at a critical investor day

Hear more about GSK’s big day here >>

More stories we’re reading today:

– Andrew